ATA. S. Tsareva

A. S. Tsareva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


A. S. Tsareva has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Platinum-containing regimens in first-line therapy for cervical cancer: efficacy and safety analysis using a pseudorandomization method

    by Alina V. Trusova, A. A. Rumyantsev, E. R. Israelyan, A. S. Tsareva, A. S. Ablyametova, A. N. Letuchikh, I. A. Pokataev, S. V. Khokhlova

    Introduction. The current standard of care for metastatic and recurrent cervical cancer (CC) is platinum- and taxane-based chemotherapy (CT). However, the choice of platinum agent remains a subject of debate. Objective. To compare the efficacy of cisplatin- and carboplatin-containing CT regimens in the first-line treatment of advanced CC. Materials and Methods. A multicenter comparative retrospective study using a pseudorandomization method (PSM analysis) was conducted, including patients with metastatic and recurrent CC who received first-line platinum-based therapy (cisplatin or carboplatin) between 2010 and 2025. The use of immunotherapy and bevacizumab in first-line therapy was permitted. Patients who received neoadjuvant/adjuvant CT were excluded. An analysis was performed using the cardinality matching (CM) method with the MatchIT package in R, balancing the groups on key covariates (age, bevacizumab, immunotherapy, history of bleeding, treatment-free interval, and presence of pelvic recurrence) at a 2:1 ratio. The standardized mean difference did not exceed 0.1 in absolute value in all cases. The primary endpoint of the study is progression-free survival (PFS); secondary endpoints are overall survival (OS) and treatment safety. Results. The study included 437 patients. After CM analysis, the carboplatin group included 228 patients, and the cisplatin group included 114 patients. The predominant histotype was squamous cell carcinoma (82.5% and 78.5%, respectively). Stage IV at baseline was observed in 37 (32.5%) and 79 (34.6%) patients. The most common metastatic site was lymph nodes, in 79 (69.3%) and 129 (56.6%) patients, respectively. At a median follow-up of 32.5 (1–141.6) months, median PFS (mPFS) was 8.27 (95% CI 7.7–9.2) mo in the carboplatin group and 8.57 (95% CI 7.5–10.4) mo in the cisplatin group; median OS (mOS) was 23.7 (95% CI 18–35) mo and 33.43 (95% CI 25.5–59.8) mo respectively. No statistically significant difference was found in mPFS (HR 0.84; 95% CI 0.66–1.1; p = 0.185) or mOS (HR 0.76; 95% CI 0.56–1.05; p = 0.100) between the groups. Carboplatin use was associated with a higher incidence of hematologic toxicity (р = 0.301), while cisplatin was associated with more vomiting (р = 0.181), diarrhea (р = 0.359), and nephrotoxicity (р = 0.004). Conclusion. The results of this retrospective study with PSM analysis showed no statistically significant difference in the efficacy of cisplatin versus carboplatin in combination with paclitaxel for metastatic and recurrent CC, with a more favorable toxicity profile for the former platinum agent.

  • Open Access

    Efficacy of pembrolizumab plus lenvatinib versus alternative drug regimens in patients with recurrent endometrial cancer after platinum based chemotherapy: a retrospective cohort study

    by Angelina N. Letuchikh, A. А. Rumyantsev, E. R. Israelyan, A. S. Ablyametova, A. V. Trusova, A. S. Tsareva, K. V. Menshikov, A. E. Protasova, M. V. Volkonsky, A. Yu. Goryainova, et al.

    Introduction. The combination of pembrolizumab and lenvatinib is the preferred second-line treatment for patients with recurrent endometrial cancer (EC) with proficient mismatch repair (pMMR) after platinum-based chemotherapy (CT). However, in real-world clinical practice, this option may be unavailable for some patients. Objective. To evaluate the efficacy of pembrolizumab plus lenvatinib compared with alternative СT regimens in patients with recurrent EC with pMMR tumor status upon progression after platinum based CT. Materials and Methods. A multicenter retrospective cohort study was conducted, including treatment data from patients with advanced and recurrent EC with рMMR tumor status from 37 oncology centers in Russia between December 2020 and December 2025. Patients were assigned to two groups according to the therapy received: immuno-targeted therapy (ITT) consisting of pembrolizumab plus lenvatinib, and alternative CT regimens, which included either platinum-based CT reinduction or non-platinum-based CT. To minimize the impact of baseline characteristic differences between the groups, patients were matched using cardinality matching (matching with maximization of the balanced sample size) at a 1:1 ratio. Group balancing was performed for the following variables: age, histological subtype, stage IV disease, receipt of radical/palliative surgery as first-line treatment, and platinum-free interval (PFI). The standardized mean difference was within ≤0.1 in absolute value for all variables. The primary endpoint was progression-free survival (PFS). Results. A total of 173 patients were enrolled in the study, of whom 106 constituted the ITT group and 67 constituted the CT group. From the initial study population, after cardinality matching, two groups of 67 patients each were formed. The median age was 60 (range, 36–80) years in the ITT group and 61 (range, 37–79) years in the alternative CT group; primary surgery was performed in 61/67 (91%) and 62/67 (93%) of patients, respectively. The median PFI was 6.9 (range, 0.0–106.5) months in the pembrolizumab–lenvatinib combination group and 9.1 (range, 0.0–69.0) months in the control group. At a median follow-up of 36.1 months (95% CI, 31.8–42.6), the median PFS in the ITT group was 9.9 months (95% CI, 7.2–12.9) versus 6.8 months (95% CI, 4.7–8.3) in the alternative CT group, which was statistically significant (HR 0.58; 95% CI, 0.40–0.85; p = 0.005). Conclusions. Treatment with the combination of pembrolizumab and lenvatinib is associated with longer PFS compared with alternative CT regimens in the matched cohort of patients with recurrent and advanced EC with MSS/pMMR tumor status upon progression after platinum-based CT.

  • Open Access

    Induction chemotherapy regimens in malignant trophoblastic tumors with high risk of resistance: retrospective study

    by A. S. Tsareva, А. А. Rumyantsev, E. R. Israyelyan, М. N. Tikhonovskaya, А. S. Shevchuk, D. Yu. Frantsev, I. V. Pogrebnyakov, G. S. Yunayev

    Background. High sensitivity of gestational throphoblastic disease (GTD) to chemotherapy makes this disease highly curable, but rapid destruction of tumor can lead to development of life-threatening complications. Low-dose chemotherapy before the main anticancer treatment can reduce these risks, but the effects on long-term outcomes are not sufficiently studied. We conducted a retrospective analysis of the N . N . Blokhin National Medical Research Center of Oncology experience in treating patients with high- and ultra-high risk GTD treated with low-dose induction or full-dose chemotherapy.Materials and methods. The monocenter comparative retrospective study included patients with high or ultra-high risk GTD who received initial treatment in 2000–2023. Patients with rare GTD subtypes, patients who had previously received any chemotherapy were excluded. Patients who received low-dose induction chemotherapy with etoposide + cisplatin comprised the experimental group, while those who received full-dose chemotherapy comprised the control group. After completion of low-dose chemotherapy, standard multidrug chemotherapy was administered until normalization of serum beta human chorionic gonadotropin (β-hCG), followed by consolidation chemotherapy. The primary endpoint of the study was 1-year progression-free survival.Results. The study included 70 patients with GTD, 21 (30 %) patients received low-dose induction chemotherapy. In this group, more patients had ECOG performance status ≥2, clinically significant bleeding, or central nervous system metastases. With median follow-up of 54.6 months, 1-year progression-free survival was 81 % in the low-dose induction chemotherapy group and 90 % in the control group, the differences were not statistically significant (hazard ratio 1.63; 95 % confidence interval 0.46–5.80; p = 0.447). Complete β-hCG response was noted in 16 (77 %) patients in the lowdose induction group and 43 (88 %) patients in control group (p = 0.231). Three-year overall survival rates were 95 % and 98 %, respectively.Conclusion. The results of this retrospective study show no differences in survival of patients with high-risk and ultra-highrisk GTD receiving low-dose induction chemotherapy. In treatment of patients with high risks of complications due to tumor process and/or drug therapy, low-risk induction chemoterhapy should be considered as an option

  • Open Access

    Aspects of hypogonadism in oncological patients receiving antitumor treatment. Literature review

    by M. E. Abramov, E. R. Israelyan, A. S. Tsareva, A. A. Rumyantsev, K. A. Firsov, V. B. Matveev

    Recent development of anticancer drug therapy and the improvement of surgical interventions have led to better oncological treatment outcomes for most patients. The introduction of targeted therapy and immuno-oncological agents into clinical practice has allowed previously incurable diseases to be transformed into chronic conditions. While focusing solely on the effectiveness of therapy, many practicing oncologists often pay little attention to another aspect – toxicity. Hypogonadism is a relatively common adverse event (AE) in men undergoing anticancer treatment. The symptoms of this AE (asthenia, erectile dysfunction, mood variability) are often mistaken for complications of drug therapy. Both chemotherapy (CT) and targeted therapy, as well as immunotherapy, can lead to hypogonadism. According to various authors, platinum-based agents can cause the development of hypogonadism in 50 % of cases among young men. Oxaliplatin-containing regimens may result in a decrease in sperm concentration following adjuvant CT for colorectal cancer. Germ cell tumors of the testis, which have high sensitivity to cisplatin-based CT, are among the most treatable malignant neoplasms, even with metastatic processes. The first stage of treatment for germ cell tumors is orchiectomy, which in itself contributes to the development of hypogonadism. Furthermore, when undergoing CT, the risk of this AE increases significantly, up to 50 % in some publications. Considering that this condition affects men of reproductive age with a very high life expectancy, careful monitoring of total testosterone levels is necessary. Uncorrected hypogonadism can lead to various late AEs: obesity, metabolic syndrome, cardiovascular pathology, and osteopenia.This literature review examines various aspects of hypogonadism in men receiving anticancer treatment and its impact on the development of late complications.

  • Open Access

    TIP regimen (paclitaxel, ifosfamide, cisplatin) in nonseminomatous germ cell tumors with poor-prognosis and unfavorable decline of serum tumor markers: final results

    by E. R. Israelyan, A. A. Tryakin, A. A. Rumyantsev, M. Yu. Fedyanin, P. V. Kononets, S. S. Gerasimov, V. B. Matveev, M. I. Volkova, A. V. Klimov, A. I. Semenova, et al.

    Background: Patients with germ cell tumors (GCTs) and poor-prognosis demonstrate unsatisfactory oncological outcomes, with a one-year progression-free survival (PFS) rate of approximately 50 %. We hypothesized that switching the chemotherapy regimen to TIP (paclitaxel, ifosfamide (mesna), cisplatin) in cases of unfavorable decline of serum tumor markers (STMs) after the first cycle of BEP (bleomycin, etoposide, cisplatin) could improve treatment outcomes in this subgroup of patients.Materials and methods: A multicenter, prospective, non-randomized phase II study included patients with nonseminomatous GCTs and poor-prognosis according to IGCCCG. All patients received the first cycle of chemotherapy in BEP regimen. Patients with an unfavorable decline of STMs subsequently received 4 cycles of TIP regimen (paclitaxel 120 mg / m² on days 1 and 2 + ifosfamide 1500 mg / m² on days 2–5 (+ mesna) + cisplatin 25 mg / m² on days 2–5 + G-CSF). In the presence of residual tumors larger than 1 cm and the technical feasibility of removal, surgical treatment was performed. The primary endpoint was one-year PFS.Results: From 2017 to 2023, 34 patients were included in the study. Enrollment was prematurely closed due to an extremely low likelihood of achieving the primary endpoint. One-year PFS and overall survival (OS) were 57.1 % and 74.4 %, respectively. The favorable response rate (complete response + partial response with normalization STM) was observed in 55,8 % of patients. Disease progression was observed in 21 patients, with the central nervous system being the first site of progression in 8 (37 %) of them. Surgical treatment was performed in 16 patients, with viable tumor obtained in 4 patients. Conducting the first cycle in a “stabilization» mode for ultra-high-risk patients did not affect PFS (p = 0.28) or OS (p = 0.434). The toxicity profile of the TIP regimen was acceptable.Conclusion: Switching from BEP to TIP for patients with nonseminomatous GCTs and an unfavorable decline of STMs did not demonstrate efficacy. Further exploration of alternative therapeutic approaches is needed to improve treatment outcomes.

  • Open Access

    Impact of PARP inhibitor maintenance therapy after initial treatment on the efficacy of subsequent therapy in ovarian cancer: a propensity score matching analysis

    by А. А. Rumyantsev, Т. Е. Tihomirova, А. S. Tsareva, S. L. Gutorov, А. N. Lud, А. P. Chernova, S. A. Tjulandin

    Introduction: progression of advanced epithelial ovarian cancer (EOC) on olaparib may diminish the efficacy of subsequent chemotherapy in recurrent disease setting. However, the impact of progression of EOC during maintenance therapy with olaparib after frontline therapy has not been well studied.Materials and methods: this retrospective study enrolled patients of BRCA / HRD + FIGO stage III–IV EOC with confirmed progressive disease after frontline treatment treated since 2014 until 2022 who either received (arm A) or not (arm B) olaparib as maintenance therapy. To ensure the balance of the compared groups during the study propensity score matching analysis was conducted (cardinality method using MatchIT package in R) with 1:1 ratio of patients in trial arms. The groups were balanced according to the presence of residual tumor after initial treatment, the duration of platinum-free interval after the frontline therapy, secondary local therapy for recurrent disease, treatment with platinum drugs for relapse and subsequent bevacizumab. The primary endpoint of the study was progression-free survival (PFS).Results: the initial population consisted of 259 patients, after the matching procedure 76 patients were enrolled in the study. The median age of patients was 48 years in the arm A and 50 years in the arm B (p = 0.989), 12 (32 %) had FIGO stage IV in both arms (p = 1.000), 25 (66 %) patients in both arms had platinum-free interval ≥ 12 months. With a median follow-up of 42.8 mo. (0.6–70.1 months) median PFS was 6.9 (95 % CI 6.2–10.6 months) and 12.2 (95 % CI 9. 6–21.3 months) in arm A and B, respectively (hazard ratio [HR] 2.89; 95 % CI 1.63–5.12; p < 0.001). Median overall survival was 23.2 months. and 68.2 mo., respectively (HR 4.15; 95 % CI 1.62–10.6).Conclusion: efficacy of subsequent chemotherapy is apparently reduced following progression of BRCA / HRD + EOC on maintenance olaparib therapy in frontline setting. Further trials should assess optimal approaches for these patients.


  • Open Access

    Treatment of a patient with disseminated testicular germ cell tumor associated with terminal chronic kidney disease requiring hemodialysis

    by A. S. Ablyametova, A. V. Zorinova, A. N. Letuchikh, E. R. Israelyan, A. S. Tsareva, A. A. Rumyantsev

    There is a cohort of cancer patients with terminal chronic kidney disease (CKD) due to various causes and requiring hemodialysis. Antitumor drug therapy in this concomitant disease is possible, but requires selection of the most optimal modified chemotherapy (CT) regimens to maximize efficacy and minimize treatment toxicity. In this case report we describe our therapeutic approach for a patient on hemodialysis with a metastatic non-seminomatous germ cell tumor (GCT) of the testis of poor prognosis according to the International Germ Cell Cancer Collaborative Group (IGCCCG) classification. We analyzed the literature datareflecting the use of different drugs and CT regimens used for the treatment of GCT in patients with CKD.

  • Open Access

    Choriocarcinoma of the ovaries: the role of molecular-genetic testing in the differential diagnosis of gestational and non-gestational forms

    by A. N. Letuchikh, A. S. Ablyametova, A. V. Zorinova, E. R. Israelyan, A. S. Tsareva, A. A. Rumyantsev

    The treatment approach for gestational and non-gestational ovarian choriocarcinoma has several differences, and their differential diagnosis requires special attention. The implementation of molecular-genetic testing which determines the presence of paternal genetic material in the tumor allows for a reliable determination of the origin of ovarian choriocarcinoma. The presented clinical case demonstrates the importance of this method in the differential diagnosis of gestational and non-gestational forms of ovarian choriocarcinoma.

  • Open Access

    Experience of using talazoparib in the aggressive course of BRCA2-associated triple-negative breast cancer: a clinical observation

    by A. S. Tsareva, E. V. Lubennikova, A. A. Rumyantsev, E. V. Glazkova, I. P. Ganshina

    The median overall survival for patients with metastatic triple-negative breast cancer is about 12-14 months. Chemotherapy has been the only treatment option for this tumour subtype for a long time, irrespective of immunological and genetic characteristics. Straightforward therapy algorithms have not been defined, and the optimum sequencing of chemotherapy regimens is left to the discretion of the attending physician. Today, impressive findings from clinical studies on the use of immunotherapy and targeted therapy for cancer using PARP inhibitors reflect in current guidelines, raising the chances of patients to prolong life and maintain its high quality. Thus, the use of immunotherapy as first-line treatment of PD-L1-positive tumours allowed to significantly increase the overall survival of patients for the first time in many years. And the use of PARP inhibitors in carriers of BRCA1/2 germline mutations not only significantly prolongs progression-free survival, but also improves quality of life versus standard chemotherapy regimens. The benefit is also observed in patients with an aggressive course of the disease such as damage to the visceral organs and the central nervous system. The presence of BRCA1/2 germline mutations in the genes, damage to the CNS and visceral organs is associated with an extremely unfavourable prognosis and a significant decline in life expectancy. However, a high-quality diagnosis before initiation of treatment, creating proper treatment plans and the use of modern opportunities can improve the outcomes of treatment. The article discusses possible treatment options for metastatic TNBC, reflects current guidelines on the use of immuno- and targeted therapy. A clinical case report of the treatment of a patient with a significantly aggravated history and an aggressive course of TNBC is presented. The patient with visceral metastases, brain damage and early progression after primary treatment has been receiving therapy for two years, while maintaining a satisfactory quality of life.

  • Open Access

    Therapy of BRCA-associated metastatic breast cancer. Efficacy and safety of talazoparib in the real-world clinical practice

    by E. V. Lubennikova, A. L. Kornietskaya, N. S. Dorofeeva, E. I. Rossokha, E. V. Markarova, I. V. Yudina, I. Y. Bazaeva, L. V. Bolotina, T. I. Deshkina, Ya. A. Zhulikov, et al.

    Introduction. PARP inhibitors demonstrated high efficacy in BRCA1/2-associated Her2-negative metastatic breast cancer (BC). They were included in the current standard chemotherapy regimen and recognized as a priority option for the treatment of such tumours following the results of clinical studies.Aim. Review the experience with talazoparib (Talzenna) in the real-world clinical practice of 6 medical centers in Russia.Materials and methods. The review included data from 29 patients with HER2-negative metastatic breast cancer associated with a gBRCA mutation, who have been receiving talazoparib therapy in 6 medical centers of Russia since April 2021. Talazoparib was given at the standard dose 1 mg once daily, the dose was reduced, if any adverse event developed.Results. The median age of the patients was 50 years. 23 patients had a BRCA1 mutation, 5 patients had a BRCA2 mutation and one of the patients had a PALB2 mutation. Prior to starting talazoparib therapy, patients had received up to 9 lines of therapy for metastatic disease, the median was 1 line. The median follow-up period at that time was only 4.6 months. The median recurrence-free survival (RFS) was not reached. Progression was observed in 10 patients with a treatment period of 1 to 7.5 months, 19 patients continued to receive PARP inhibitor therapy without signs of disease progression, with a treatment period of 2 to 18 months. The objective response rate (ORR) was 57.2%, the clinical efficacy was confirmed in 85.7% of cases. The subgroup analysis showed that the lowest efficacy of therapy was reported in the group of patients, who had received prior therapy with platinum-based drugs, the median progression-free time (mPFT) was 4.5 months. (95% CI: 1.79-9.2). While for patients who had not received the prior platinum drug regimens, the median was not reached. Haematologic toxicities were common adverse events (AEs) for the talazoparib therapy, which were reported in 34.5% of cases. Transfusions of blood components were required in 3 patients, one of them required them repeatedly. All dose modifications were due to hematological toxicities. 7 patients (24.1%) required a dose reduction and 3 patients (10.3%) - repeated dose reduction.Conclusions. Testing for BRCA1/2 mutations in Her2-negative mBC should be a mandatory diagnostic procedure. Talazoparib therapy is an effective and safe treatment option for patients with gBRCAmut HER2-mBC.